Results 291 to 300 of about 452,381 (401)
Abstract Aims The prevalence of diabetes and obesity continues to rise in women of reproductive age, with significant implications for both mother and foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments of diabetes and obesity. However, no Glucagon‐like peptide‐1 receptor agonists are currently approved for use during pregnancy ...
Claire H. Parker+3 more
wiley +1 more source
Therapeutic role of Crateva religiosa in diabetic nephropathy: Insights into key signaling pathways. [PDF]
Ali M+8 more
europepmc +1 more source
Abstract Aims To assess the incidence of macrovascular and microvascular complications in US Medicare enrollees diagnosed with T2D with and without established ASCVD. Materials and Methods We conducted a retrospective cohort study using Medicare fee‐for‐service claims data from 1 January 2006, through 31 December 2021. Baseline demographic and clinical
Tyler J. Dunn+6 more
wiley +1 more source
Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection. [PDF]
Errabelli P+3 more
europepmc +1 more source
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus+7 more
wiley +1 more source
Optimizing preparation of renal biopsy specimens for TEM: a time-efficient approach to rapid diagnosis of kidney diseases. [PDF]
Wang G+5 more
europepmc +1 more source
Abstract Aims This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase‐4 inhibitor (DPP‐4i) in the United Kingdom (UK), Sweden, and Finland.
Niklas Schmedt+6 more
wiley +1 more source
Immunoglobulin M Nephropathy: A Diagnostic Dilemma Between Minimal Change Disease and Focal Segmental Glomerulosclerosis. [PDF]
Agrawal G+3 more
europepmc +1 more source